A5101505164- Protein Tyrosine Phosphatases
- Galectins and Cancer Biology
- Cytokine Signaling Pathways and Interactions
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- RNA modifications and cancer
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Gastrointestinal Tumor Research and Treatment
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Renal cell carcinoma treatment
- Metastasis and carcinoma case studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
Nanjing Medical University
2012-2024
Jiangsu Province Hospital
2012-2024
Tyrosine phosphatase SHP2 is a promising drug target in cancer immunotherapy due to its bidirectional role both tumor growth promotion and T-cell inactivation. Its allosteric inhibitor SHP099 known inhibit cell vitro vivo. However, whether SHP099-mediated inhibition retards vivo via anti-tumor immunity remains elusive. To address this, CT-26 colon xenograft model was established mice since this line insensitive SHP099. Consequently, minimally affected immuno-deficient nude mice, but...
The side effects of current immunosuppressive drugs have impeded the development therapies for immune diseases. Selective regulation STAT signaling is an attractive strategy treating disorders. In this study, we used a small-molecule compound to explore possible means targeting STAT1 treatment Th1-mediated inflammation. in T cells from C57BL/6 mice was accomplished using fusaruside, that triggers tyrosine phosphorylation Src homology 2-containing protein phosphatase 2 (SHP-2). interaction...
Background: Gastrectomy with D2 lymphadenectomy is a standard procedure of curative resection for gastric cancer (GC). The aim this study was to develop simple and reliable prognostic scoring system GC treated gastrectomy combined adjuvant chemotherapy. Methods: A established based on clinical laboratory data from 579 patients localized without distant metastasis Results: From the multivariate model overall survival (OS), five factors were selected system: ≥50% metastatic lymph node rate,...
Purpose: Colon cancer is a common malignant tumor of the digestive system.This project verified negative role protein tyrosine phosphatase (SHP-2) in regulation colon and further clarified key targets molecular mechanisms process. Patients Methods:The expression levels SHP-2 tissues, adjacent normal cell lines, lines were detected via Quantitative Realtime PCR (qRT-PCR).The effect on function was using proliferation, Transwell, scratch, apoptotic assays.CD81 identified as interaction by...
3574 Background: CPGJ602 is a recombinant anti-EGFR human-mouse chimeric monoclonal antibody. plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) may have efficacy in KRAS/NRAS/BRAF wild-type metastatic colorectal cancer. Methods: In this open-label, randomized trial, patients who had received no previous treatment were randomly assigned (2:2:1) to receive CPGJ60（325mg/m 2 , q2w) mFOLFOX6 (biweekly group), (400 mg/m initial dose followed by 250 /week thereafter) (weekly group)...
Pancreatic cancer is one of the most malignant tumors due to its highly aggressive nature, but pancreatic metastases colorectum are extremely rare. A 43-year-old male patient complained increased stool frequency. Colonoscopy revealed a prominence lesion in rectum and computed tomography (CT) scan confirmed rectal mass. CT also showed retroperitoneal masses tail involving spleen adjacent blood vessels. The was initially misdiagnosed as having with metastasis. After immunohistochemical...